DTU researchers report synthetic mRNA vaccine candidate reduced allergic reactions in mice against multiple food allergens
DTU researchers reported in Nature Communications that a synthetic allergen delivered by an mRNA vaccine induced protective antibodies and reduced allergic reactions in mice exposed to several related food allergens. The finding is a preclinical proof of concept, not evidence of a human vaccine.
DTU Bioengineering researchers developed a vaccine using synthetic allergen fragments that share molecular features with widespread allergens in peaches and certain nuts. The team packaged the allergen instructions in an mRNA platform, similar to COVID-19 vaccines, to train the immune system to make protective antibodies rather than tolerate increasing allergen doses. The study, published in Nature Communications, tested the approach in healthy mice and allergic mice after three doses given at three-week intervals.
After one dose, healthy mice produced large quantities of protective antibodies. After three doses, vaccination elicited a broad antibody response against a range of related allergens. In allergic mice, the vaccine also increased protective antibodies and was associated with virtually no observed side effects, although it did not provide full protection against anaphylaxis at the tested concentration and dose schedule. Laboratory tests with patient blood samples showed mouse-derived antibodies could reduce allergic reactions in vitro.
The work addresses a field where the only potentially disease-modifying treatments are allergen immunotherapies, which expose patients over years to increasing amounts of a specific allergen by injection or tablet. Many people instead avoid trigger foods and cross-reactive substances. U.N. figures cited in the report estimate more than 220 million people worldwide have food allergies. The DTU approach differs by using a synthetic allergen designed to cover related proteins, rather than gradually desensitizing a patient to one known allergen.
The result matters because a single vaccine against a family of allergens addresses a major daily-life burden for people with multiple food allergies, including ingredient checking and avoidance. The evidence remains preclinical: mice and patient blood samples can show immune responses and laboratory reduction of allergic reactions, but cannot establish efficacy, optimal dose, durability, or safety in people. Controlled human trials would need to measure real food challenge outcomes, not only antibody levels.
People with multiple food allergies face constant avoidance and ingredient checking, and a broader vaccine approach could reduce that burden if human trials show real protection. The current mouse and lab data cannot establish clinical benefit or safety.
Sources (1)
- [1]Eating without fear: A single vaccine shows promise against multiple food allergies(https://medicalxpress.com/news/2026-11-vaccine-multiple-food-allergies.html)